Agreements reached under this partnership
Capital and Business Alliance- 1
The Company holds warrants in Isofol Medical AB equivalent to 2,083,332 shares and will exercise all of them.
- 2
The funds will be allocated to part of the SP-05 clinical trial.
- 3
Deepen future collaboration with Isofol Medical AB.
- 4
Benefit from part of the economic value generated by progress in SP-05 development outside Japan.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The Company expects to benefit from part of the economic value generated by progress in SP-05 development. Forward-looking statements do not constitute a commitment to achieve them, and actual results and other factors may vary.
| Item | Details |
|---|---|
| Name of alliance partner | Isofol Medical AB |
| Alliance partner's business activities | Licensor of rights to SP-05 (alholitixorin) / development partner / global original rights holder |
| Alliance partner's location | Sweden |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | The Company holds warrants in Isofol Medical AB equivalent to 2,083,332 shares and will exercise all of them., The funds will be allocated to part of the SP-05 clinical trial., Deepen future collaboration with Isofol Medical AB., Benefit from part of the economic value generated by progress in SP-05 development outside Japan. |
| Number of shares acquired | Equivalent to 2,083,332 shares; percentage of total shares outstanding: Not disclosed |
| Acquisition price | SEK 1,979,165.4 (Swedish krona) |
| Shareholding ratio | 3.25% → Not disclosed |
| Shareholding Policy | The shares to be acquired will not be subject to a continuing holding lock-up, ensuring a certain degree of liquidity. |
| Impact on Business Performance | The Company expects to benefit from part of the economic value generated by progress in SP-05 development. Forward-looking statements do not constitute a commitment to achieve them, and actual results and other factors may vary. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The shares to be acquired will not be subject to a continuing holding lock-up, ensuring a certain degree of liquidity; the Phase Ib/II clinical trial for SP-05 is progressing smoothly, supporting expectations for further growth in Isofol Medical AB's enterprise value; part of the additional investment will be allocated to the SP-05 clinical trial; and the Company expects to deepen its collaboration with Isofol Medical AB and benefit from part of the economic value generated by progress in SP-05 development outside Japan.